Article Text

Download PDFPDF
Review: metformin is effective at attenuating the metabolic risks associated with use of atypical antipsychotics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.



Can metformin reduce the degree of weight gain and insulin resistance associated with use of atypical antipsychotic agents?


Changes in anthropometric measures including body weight, body mass index, waist circumference and insulin resistance in individuals taking atypical antipsychotics (AAP). Insulin resistance was determined using the homeostasis model assessment of insulin resistance (HOMA-IR) which is calculated as (fasting insulin in µU/ml × fasting blood glucose in mg/dl)/405.



Systematic review and meta-analysis.

Data sources

MEDLINE, EMBASE, Cochrane CENTRAL were systematically searched up to 31 December 2008. Hand searching for additional studies from reference lists of other studies and reviews was also conducted.

Study selection and analysis

Randomised, placebo controlled trials were included if they assessed metformin use in participants taking AAP and had adequate reporting of anthropometric measures, including insulin resistance. No exclusions were made on the basis of language. Studies were independently assessed by two reviewers who also assigned Jadad scores to the included studies to assess methodological strength based on reporting of randomisation, double blinding and loss to follow-up. …

View Full Text


  • Sources of funding None.


  • Competing interests None.